Five individuals did not respond when retreated again twice, 2 weeks apart, with the same or higher dose. weeks. In all dose groups, injection reactions CH5132799 were transient and slight to moderate; there were no other security issues. Forty-seven response-evaluable individuals experienced 23 (49%) objective reactions (platelet counts 30109/L and 2 baseline) including 15 (32%) […]